Study / Cell-based assay / Prevalence of MOG-IgG seropositivity
Demyelinating disease / Control
Lalive et al. (2006)1 / FACS: full-length MOG, plasmid vector, stable expression in CHO cells, serum dilution 1:10 / 10/128(8%)* / 1/37 (3%)*
Zhou et al. (2006)2 / FACS: full-length MOG, lentiviral, stable expression in LN18 human glioblastoma cells, serum dilution 1:36 / 59/210 (28%) / 8/187 (4%)
O’Connor et al. (2007)3 / FACS: full-length MOG N-terminally fused to GFP, plasmid vector, stable expression in Jurkat cells, serum dilution 1:50 / 8/52 (15%) / 0/11 (0%)
McLaughlin et al. (2009)4 / FACS: full-length MOG N-terminally fused to GFP, plasmid vector, stable expression in Jurkat cells, serum dilution 1:50 / 41/428 (10%) / 6/214 (3%)
Brilot et al. (2009)5 / FACS: full-length MOG, lentiviral vector, stable expression in LN18 human glioblastoma cells, serum dilution 1:100, high-titre cut-off >109 delta median fluorescence intensity / 18/101 (18%) / 0/73 (0%)
Selter et al. (2010)6 / FACS: full-length MOG, lentiviral vector, stable expression in LN18 human glioblastoma cells, serum dilution 1:100, high-titre cut-off >109 delta median fluorescence intensity / 18/44 (41%) / 0/58 (0%)
Di Pauli et al. (2011)7 / Immunofluorescence assay: full-length MOG C-terminally fused to EmGFP, plasmid vector, transient expression in HEK293 cells, serum dilution 1:20, high-titre cut-off ≥1:160 / 20/161 (12%) / 1/105 (1%)
Lalive et al. (2011)8 / FACS : full-length MOG, plasmid vector, stable expression in CHO cells, serum dilution 1:10 / 4/33 (12%) / 0/20 (0%)
Pröbstel et al. (2011)9 / FACS: full-length MOG, plasmid vector, stable expression in TE671 cells, serum dilution 1:50 / 35/188 (19%) / 0/63 (0%)
Mader et al. (2011)10 / Immunofluorescence assay: full-length MOG C-terminally fused to EmGFP, plasmid vector, transient expression in HEK293 cells, serum dilution 1:20, high-titre cut-off ≥1:160 / 28/232 (12%) / 3/101 (3%)
Rostàsy et al. (2012)11 / Immunofluorescence assay: full-length MOG C-terminally fused to EmGFP, plasmid vector, transient expression in HEK293 cells, serum dilution 1:20, high-titre cut-off ≥1:160 / 17/37 (46%) / NA
Kitley et al. (2012)12 / Immunofluorescence assay: full-length MOG N-terminally fused to EmGFP, plasmid vector, transient expression in HEK293 cells, serum dilution 1:20 / 4/146 (3%) / 0/47 (0%)
Rostàsy et al. (2012)13 / Immunofluorescence assay: full-length MOG C-terminally fused to EmGFP, plasmid vector, transient expression in HEK293 cells, serum dilution 1:20, high-titre cut-off ≥1:160 / 22/103 (21%) / 0/23 (0%)
All studies / 3–46% / 0–4%
*Frequencies were calculated assuming a cut-off of >1 binding ratio. Abbreviations: CHO, Chinese hamster ovary; EmGFP, emerald GFP; FACS, fluorescence-activated cell sorting; GFP, green fluorescent protein; HEK, human embryonic kidney; MOG, myelin oligodendrocyte glycoprotein; NA, not analysed.
1. Lalive, P.H. etal. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc. Natl Acad. Sci. USA 103, 2280–2285 (2006).
2. Zhou, D. etal. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl Acad. Sci. USA 103, 19057–19062 (2006).
3. O’Connor, K.C. etal. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 13, 211–217 (2007).
4. McLaughlin, K.A. etal. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J. Immunol. 183, 4067–4076 (2009).
5. Brilot, F. etal. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann. Neurol. 66, 833–842 (2009).
6. Selter, R.C. etal. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 74, 1711–1715 (2010).
7. Di Pauli, F. etal. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin. Immunol. 138, 247–254 (2011).
8. Lalive, P.H. etal. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult. Scler. 17, 297–302 (2011).
9. Probstel, A.K. etal. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77, 580–588 (2011).
10. Mader, S. etal. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J. Neuroinflamm. 8, 184 (2011).
11. Rostásy, K. etal. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch. Neurol. 69, 752–756 (2012).
12. Kitley, J. etal. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79, 1273–1277 (2012).
13. Rostásy, K. etal. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin4 antibody negative pediatric neuromyelitis optica. Mult. Scler. http://dx.doi.org/10.1177/1352458512470310.